Melbourne Australia: Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY) will today present at the Bell Potter LifeScience Conference for professional and sophisticated investors.

The conference is expected to be attended by more than 150 people including the leading institutional investors, high net-worth investors, and other influential industry players.

It follows Starpharma’s success in winning the Company of the Year Award presented last night as part of the Janssen 2012 Industry Excellence Awards at the AusBiotech 2012 Conference.

Starpharma chief executive officer Jackie Fairley will be presenting. 

Highlights of the presentation include:

VivaGel^® Bacterial Vaginosis:  This program is nearing completion with the completion of recruitment in the two Phase 3 studies for VivaGel^® as a treatment for BV.  Results are expected to be available by early December 2012.

 A Phase 2 clinical trial to investigate the ability of VivaGel^® to prevent the recurrence of BV is now also fully recruited, and completion of this trial is on track for Q4 2012 with results expected early in 2013.

Drug delivery program:  New data demonstrates Starpharma’s dendrimer-docetaxel formulation has significant tumour-targeting results.  Starpharma’s partnered program is also progressing with a partnership allowing global pharmaceutical giant AstraZeneca to test whether Starpharma dendrimer molecules could enhance the effectiveness of existing cancer drugs.

Agrochemical program:  A new dendrimer-glyphosate (the active ingredient in Roundup^®) formulation demonstrated improved efficacy and rain-fastness in Starpharma’s internal agrochemical program.  Starpharma also has a collaboration that will see its dendrimer technology used to develop innovative crop protection formulations for Nufarm’s product portfolio.

Download ASX Announcement Starpharma presenting at Bell Potter LifeScience Conference ( pdf file, 2MB)